Last reviewed · How we verify
Edetate Calcium Disodium
Edetate calcium disodium is a chelating agent that binds and removes heavy metals (particularly lead) from the body by forming stable complexes that are excreted in urine.
Edetate calcium disodium is a chelating agent that binds and removes heavy metals (particularly lead) from the body by forming stable complexes that are excreted in urine. Used for Lead poisoning (acute and chronic lead toxicity), Heavy metal poisoning.
At a glance
| Generic name | Edetate Calcium Disodium |
|---|---|
| Also known as | Calcium Disodium Versenate, Calcium EDTA, C10H12CaN2Na2O8, Calcium disodium edetate, Calcium Disodium Ethylenediaminetetraacetate |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Chelating agent |
| Target | Heavy metal ions (lead, cadmium, zinc, and other divalent/trivalent cations) |
| Modality | Small molecule |
| Therapeutic area | Toxicology |
| Phase | FDA-approved |
Mechanism of action
The drug contains a chelate structure with multiple binding sites that preferentially bind divalent and trivalent metal cations, especially lead, while releasing calcium. It forms soluble complexes with heavy metals in the bloodstream and tissues, facilitating their urinary elimination without significantly depleting essential minerals when used appropriately.
Approved indications
- Lead poisoning (acute and chronic lead toxicity)
- Heavy metal poisoning
Common side effects
- Nephrotoxicity (kidney damage)
- Hypocalcemia (low blood calcium)
- Zinc depletion
- Fever
- Headache
Key clinical trials
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (PHASE1)
- Repurposing Tilmanocept for Cardiac Sarcoidosis (PHASE2)
- To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse. (NA)
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
- Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®. (NA)
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |